Myocardial Infarction – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Myocardial Infarction – Drugs In Development, 2023’, provides an overview of the Myocardial Infarction pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Myocardial Infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction
- The report reviews pipeline therapeutics for Myocardial Infarction by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Myocardial Infarction therapeutics and enlists all their major and minor projects
- The report assesses Myocardial Infarction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Myocardial Infarction
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Abarceo Pharma ABAbcentra LLC
Acticor Biotech SAS
Albert Einstein College of Medicine
Animatus Biosciences LLC
Ankasa Regenerative Therapeutics Inc
Aposcience AG
APstem Therapeutics Inc
APT Therapeutics Inc
AptaTargets SL
Argenica Therapeutics Ltd
AstraZeneca Plc
Athera Biotechnologies AB
Axolo Pharma Inc
Bayer AG
Beijing Northland Biotech Co Ltd
Beijing Tide Pharmaceutical Co Ltd
Biogen Inc
BlueRock Therapeutics LLC
Boehringer Ingelheim International GmbH
Brexogen Inc
Cardior Pharmaceuticals GmbH
CeleCor Therapeutics Inc
Celixir Ltd
Cell Tech Pharmed Co
Cellix Bio Pvt Ltd
CellProthera SAS
CervoMed Inc
CFM Pharma Holding BV
Chengdu Shibeikang Biomedical Technology Co Ltd
Cynata Therapeutics Ltd
DeckTherapeutics Inc
Diapin Therapeutics LLC
Domainex Ltd
East Carolina University
Eight Plus One Pharmaceutical Co Ltd
Elicio Therapeutics Inc
EndoProtech Inc
Ever Supreme Bio Technology Co Ltd
Evotec SE
EyeGene Inc
Faraday Pharmaceuticals Inc
Federal University of Minas Gerais
Freeline Therapeutics Holdings Plc
Generium
Gifu University School of Medicine
Hannover Medical School
Hemostemix Inc
Heqet Therapeutics Srl
Hetero Biopharma Ltd
Honya Medical Inc
HUYA Bioscience International LLC
Idorsia Pharmaceutical Ltd
iHeart Japan Corp
Immunwork Inc
InCarda Therapeutics Inc
Infensa Bioscience Pty Ltd
Innolife Co Ltd
Inotrem SA
Institute of Biotechnology and Pharmaceutical Research
Jinan University
Kancera AB
KARE Biosciences Inc
Life Sciences Institute
MandalMed Inc
Mesoblast Ltd
MicroCures Inc
MimeTech Srl
Mirae Cell Bio Co Ltd
New World Laboratories Inc
Nexel Co Ltd
North Carolina State University
Novartis AG
Novo Nordisk AS
NuvOx Pharma LLC
Omeros Corp
Orio Therapeutics SA
Osaka University Hospital
OtiTopic Inc
Ottawa Hospital Research Institute
Pharmahungary Group
Polygon Therapeutics SAS
Primary Peptides Inc
Qurgen Inc
R-Pharm
Recardio Inc
RegenInnopharm Inc
Remd Biotherapeutics Inc
ResoTher Pharma ApS
Ribomic Inc
Rion Inc
River BioMedics BV
Rubicon Biotechnology Inc
Saje Pharma LLC
Sentan Pharma Inc
Serca Pharmaceuticals AS
Serpin Pharma LLC
Shilpa Biologicals Pvt Ltd
Silver Creek Pharmaceuticals Inc
SmartPharm Therapeutics Inc
Sorrento Therapeutics Inc
Stemmeditech Inc
T&R Biofab Co Ltd
Taiwan Bio Therapeutics Co Ltd
Tasly Pharmaceutical Group Co Ltd
Techfields Pharma Co Ltd
Tel Aviv University
The Scripps Research Institute
Thea Open Innovation SASU
Theertha Biopharma Pvt Ltd
Thrombolytic Science International LLC
TNAX Biopharma Corp
Translational Sciences Inc
TreeFrog Therapeutics SAS
U.S. National Institutes of Health
UAB Minority Health and Health Equity Research Center
University College of Medical Sciences
University of California Los Angeles
University of Cape Town
University of Illinois
University of Kansas
University of Strasbourg
University of Sydney
University of Vienna
Vanderbilt University
Vaxil Bio Therapeutics Ltd
Westwood Therapeutics Inc
XBiotech Inc
Yichang Humanwell Pharmaceutical Co Ltd
Yuyu Pharma Inc
Zensun (Shanghai) Sci & Tech Co Ltd
Zonhon Biopharma Institute Inc
Zydus Lifesciences Ltd
Zylem Biosciences Inc